Gene - editing tech firm Inscripta has made the strategic acquisition of life sciences company Solana labs for an undisclosed amount . The deal aims to speed up the commercialisation of Inscripta 's CRISPR - based gene - editing software tools , and will see gene lab Tom Rosso – a former Illumina executive – become VP of operations .
Gene-editing tech firm Inscripta has made the strategic acquisition of life sciences company Solana Biosciences for an undisclosed sum. The deal aims to speed up the commercialisation of Inscripta's CRISPR-based gene-editing technology tools, and will see Solana CEO Tom Rosso – a former Illumina executive – become VP of operations.